Study guide
11.2 Respiratory Pharmacotherapy
ANCC Family Nurse Practitioner FNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy
2 Assessment Foundations
2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules
3 Function, Risk, and Lifespan Assessment
3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment
4 Diagnosis Foundations
4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change
5 Differential Diagnosis
5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps
6 Prevention and Anticipatory Guidance
6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan
7 Guidelines, Culture, and Evidence
7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal
8 Care Plans and Shared Decisions
8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions
9 Pharmacotherapeutics
9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety
10 Cardiovascular Primary Care
10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues
11 Respiratory Primary Care
11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care
12 Endocrine and Metabolic Primary Care
12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease
13 Gastrointestinal Primary Care
13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care
14 GU, Renal, and Reproductive Primary Care
14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function
15 HEENT, Skin, and Musculoskeletal
15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care
16 Neuro, Psych, Heme, Immune, and Infection
16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives
17 Clinical Delivery Skills
17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation
18 Professional Practice
18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role
19 Outcome Evaluation
19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy
20 Follow-Up, Systems, and Exam Strategy
20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review
11.2 Respiratory Pharmacotherapy
Key Takeaways Explain This Topic AI
GINA Track 1 for adolescents and adults uses ICS-formoterol as the anti-inflammatory reliever: Steps 1–2 as-needed, Step 3 low-dose MART, Step 4 medium-dose MART. SABA-only therapy is not preferred.
GOLD COPD is built on LAMA/LABA dual bronchodilation; add ICS when blood eosinophils are high or exacerbations keep happening — not as automatic monotherapy for every smoker.
Montelukast carries an FDA boxed warning for serious neuropsychiatric events; it does not replace inhaled corticosteroid as the preferred asthma controller.
Inhaler technique — device type, spacer for many MDIs, rinse after ICS — is part of the prescription. A perfect molecule in a poorly used device is a failed Implementation item.
Outpatient adult CAP follows current IDSA options and local resistance (amoxicillin or doxycycline first-line in many healthy outpatients); do not automatically write azithromycin. Start oseltamivir within 48 hours of influenza symptoms when treating.
Last updated: August 2026
The current FNP-BC Test Content Outline lists respiratory among the official drug-agent classes . Domain III Planning asks whether you chose an evidence-based regimen; Domain IV Implementation asks whether the dose, device, interaction, and counseling are safe. This is the prescribing chapter that sits on top of the diagnoses in Section 11.1.
GINA 2025/2026: no more SABA-only asthma care
For adolescents and adults , GINA’s core rule is simple enough to quote on a test: every patient receives ICS-containing therapy . SABA-only treatment is not preferred . As-needed albuterol without an anti-inflammatory reliever or a daily ICS leaves airway inflammation untreated, is linked to more exacerbations, and is the outdated pattern the exam still uses as a foil.
Track 1 is preferred. The reliever is ICS-formoterol (an anti-inflammatory reliever). Steps 1–2 use as-needed ICS-formoterol only — no mandatory daily maintenance if symptoms are infrequent. Step 3 is low-dose MART (maintenance-and-reliever therapy): the same ICS-formoterol inhaler is taken every day and used for relief. Step 4 is medium-dose MART . Step 5 (add-on LAMA, phenotype-guided biologic referral, consideration of higher-dose ICS-formoterol) is usually comanagement, not a first FNP solo move.
Track 2 is the alternative when Track 1 is not available or not accepted: daily ICS or ICS-LABA maintenance, with a SABA or ICS-SABA reliever. Track 2 still forbids SABA as the only drug. If you use a SABA reliever, there must be an ICS in the plan — either daily or in the reliever combination.
MART only works with a fast-onset LABA that is approved for relief — in practice, formoterol . You cannot tell a patient to use maintenance fluticasone-salmeterol “as a rescue puff.” Salmeterol is too slow and is not a reliever. Write the device, the as-needed ceiling, and the action-plan yellow zone so the patient does not invent a second, SABA-only inhaler that undoes the strategy.
- Track Reliever Steps 1–2 Step 3 Step 4
- Track 1 (preferred) ICS-formoterol As-needed ICS-formoterol Low-dose MART Medium-dose MART
Track 2 (alternative) SABA or ICS-SABA Low-dose ICS whenever SABA is used, or daily ICS Daily low-dose ICS-LABA Daily medium-dose ICS-LABA
COPD pharmacotherapy: GOLD in one page
After spirometry confirms obstruction, GOLD ABE drives the first maintenance inhaler. Group A (few symptoms, rare exacerbations) can start with a bronchodilator. Groups B and E are built on LAMA/LABA dual long-acting bronchodilation as the foundation — not an inhaled steroid first and not a standing SABA as “the COPD inhaler.” Add ICS when blood eosinophils are high or exacerbations keep happening (especially hospitalizations) despite dual bronchodilation. Low eosinophils make ICS less useful and raise pneumonia risk without much benefit. Smoking cessation is disease-modifying; no inhaler replaces it. Long-term oxygen is for chronic severe hypoxemia and needs specialty confirmation of the saturation/PaO2 criteria and a safe home plan — do not send a concentrator home from a single clinic spot-check of 91% in a patient who just walked in from the parking lot.
A SABA still has a role as true rescue for sudden bronchospasm in COPD and as a clinic nebulizer during an exacerbation. It is not controller therapy. Combining four controllers without reviewing technique is how frail adults end up on a DPI they cannot inhale.
ICS, LABA, LAMA, and why the device matters
Inhaled corticosteroids treat eosinophilic airway inflammation. They are the backbone of asthma control and a targeted add-on in COPD. Local harms are thrush and dysphonia — rinse and spit after ICS, and use a spacer with many MDIs. High-dose, long-duration ICS can affect bone, skin, eyes, and the adrenal axis, but that risk is still smaller than repeated systemic steroid courses. Do not “protect the bones” by stopping ICS in a pregnant or poorly controlled asthmatic (Section 11.3).
ICS-LABA combinations are Track 2 maintenance and the usual COPD add when ICS is indicated. Never prescribe LABA monotherapy for asthma — that is a safety error, not a style difference. LAMA (tiotropium and class peers) is COPD foundation therapy and an add-on in severe asthma. Watch for dry mouth, urinary retention, and glaucoma symptoms in older men with prostatic hypertrophy.
SABA (albuterol, levalbuterol) relaxes smooth muscle within minutes. Teach it as rescue or as the Track 2 reliever paired with ICS , not as a lifestyle. Using a canister every few weeks is a control problem; using one every few days is an exacerbation or a Step-up signal. Prime MDIs, shake MDIs, and do not shake most DPIs . Slow deep inhalation for MDI; fast deep inhalation for DPI. Recheck technique at every respiratory visit. If the patient cannot coordinate an MDI, add a spacer or change the device. Writing “albuterol 2 puffs q4h prn” without naming the device and watching a demonstration is an incomplete prescription.
Montelukast, oral steroids, and inhaled versus systemic
Leukotriene receptor antagonists — montelukast is the one you will see — can help allergic rhinitis plus asthma, exercise-induced symptoms, and aspirin-exacerbated respiratory disease. They are not preferred standalone controllers and they do not replace ICS at GINA Step 3. Teach the boxed warning: montelukast is associated with serious neuropsychiatric events — agitation, depression, sleep disturbance, and suicidal thinking . Counsel every patient (and parent) before the first fill, stop the drug if mood or behavior changes, and do not start it casually because “the child hates inhalers.” Fix the device and the action plan first.
Systemic corticosteroids are for exacerbations and for a few steroid-responsive rare diseases, not for monthly “tune-ups.” Adult asthma or COPD exacerbation courses are short (often about five days of prednisone in the 40–50 mg range for many adults; pediatric weight-based bursts follow local/NAEPP-style practice). Short bursts usually do not need a taper . Recheck why the patient needed the third burst this year — that is a controller and trigger problem, not a reason to leave them on 10 mg daily from the primary-care bottle. Inhaled steroid treats day-to-day inflammation with a fraction of the systemic exposure; oral steroid treats the flare. Do not substitute a dexamethasone injection for a missing ICS inhaler in chronic asthma.
Antibiotics for outpatient pneumonia — and influenza timing
For outpatient adult CAP , follow current IDSA adult outpatient options and local pneumococcal macrolide resistance . In many previously healthy outpatients that means high-dose amoxicillin or doxycycline . A macrolide is reasonable only when local macrolide resistance is known to be low . Do not give azithromycin automatically. Patients with comorbidities often need a beta-lactam plus a macrolide or doxycycline, or a respiratory fluoroquinolone reserved for when other options fail or are contraindicated — fluoroquinolones carry FDA warnings (tendon, aortic, hypoglycemia, CNS) that make them a considered choice, not a default z-pack substitute. Duration is often about five days if the patient is clinically stable; longer automatic courses are not a virtue. Bronchitis without pneumonia still does not get an antibiotic.
Oseltamivir (and other approved influenza antivirals) help most when started within 48 hours of symptom onset . Treat high-risk outpatients and anyone sick enough to need hospital care even if the clock has run past 48 hours; do not withhold treatment from a day-three pregnant patient or a hypoxic older adult because a handout said “only 48 hours.” Oseltamivir does not replace influenza vaccination and it does not treat bacterial pneumonia. If influenza is in the differential and the patient is eligible, start the antiviral; do not wait for a send-out that returns after the treatment window.
FNP traps: refilling albuterol without an ICS-containing plan; using salmeterol as a MART reliever; adding montelukast to avoid an inhaler teaching visit; treating COPD with ICS monotherapy; writing azithromycin for every infiltrate and every winter cough; and starting home oxygen or a 21-day steroid taper because the last clinic did it. Prescribe the class that matches the guideline track, then watch the patient use the device.